XtriG is a patented technology for sub labial drug delivery based on carbohydrate structures. The technology is primarily intended to be an attractive alternative to the ingestion of tablets.
Compared to ingesting tablets, the advantages of drug administration via the oral mucosa are several; faster onset, lower dosage, fewer side effects and less strain on the environment. The advantages have been well-known for a long time, but oral mucosal drug delivery is difficult and drugs are as a rule washed away by the saliva before they are absorbed.
XtriG aims at solving the problems and the goal is a technology platform that is compatible with a wide range of pharmaceuticals.